title: Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma.
abstract: OBJECTIVE
  We evaluated the use and effectiveness of beta-blocker therapy after acute myocardial infarction (AMI) for elderly patients with chronic obstructive pulmonary disease (COPD) or asthma.
  
  
  BACKGROUND
  Because patients with COPD and asthma have largely been excluded from clinical trials of beta-blocker therapy for AMI, the extent to which these patients would benefit from beta-blocker therapy after AMI is not well defined.
  
  
  METHODS
  Using data from the Cooperative Cardiovascular Project, we examined the relationship between discharge use of beta-blockers and one-year mortality in patients with COPD or asthma who were not using beta-agonists, patients with COPD or asthma who were concurrently using beta-agonists and patients with evidence of severe disease (use of prednisone or previous hospitalization for COPD or asthma) compared with patients without COPD or asthma.
  
  
  RESULTS
  Of 54,962 patients without contraindications to beta-blockers, patients with COPD or asthma (20%) were significantly less likely to be prescribed beta-blockers at discharge after AMI. After adjusting for demographic and clinical factors, we found that beta-blockers were associated with lower one-year mortality in patients with COPD or asthma who were not on beta-agonist therapy (relative risk [RR] = 0.85, 95% confidence interval [CI] 0.73 to 1.00), similar to patients without COPD or asthma (RR = 0.86, 95% CI 0.81 to 0.92). A survival benefit for beta-blockers was not found among patients concurrently using beta-agonists or with severe COPD or asthma.
  
  
  CONCLUSIONS
  Beta-blocker therapy after AMI may be beneficial for COPD or asthma patients with mild disease. A survival benefit was not found for elderly AMI patients with more severe pulmonary disease.
authors.affiliation: Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
authors.forename: J
authors.initials: J
authors.lastname: Chen
authors.forename: M J
authors.initials: MJ
authors.lastname: Radford
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.forename: T A
authors.initials: TA
authors.lastname: Marciniak
authors.forename: H M
authors.initials: HM
authors.lastname: Krumholz
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000367:Age Factors; D000368:Aged; D001249:Asthma / Q000150:complications*; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000150:complications*; D008297:Male; D009203:Myocardial Infarction / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate
chemical_list: D000319:Adrenergic beta-Antagonists